Human papillomavirus-related squamous cell carcinomas after blood or marrow transplantation-a Blood or Marrow Transplant Survivor Study report.

IF 9.9 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute Pub Date : 2025-06-01 DOI:10.1093/jnci/djaf021

Anna Sällfors Holmqvist, Qingrui Meng, Wendy Landier, Lindsey Hageman, Liton F Francisco, Elizabeth Schlichting Ross, Nora Balas, Alysia Bosworth, Hok Sreng Te, Ravi Bhatia, F Lennie Wong, Daniel Weisdorf, Saro H Armenian, Smita Bhatia

{"title":"Human papillomavirus-related squamous cell carcinomas after blood or marrow transplantation-a Blood or Marrow Transplant Survivor Study report.","authors":"Anna Sällfors Holmqvist, Qingrui Meng, Wendy Landier, Lindsey Hageman, Liton F Francisco, Elizabeth Schlichting Ross, Nora Balas, Alysia Bosworth, Hok Sreng Te, Ravi Bhatia, F Lennie Wong, Daniel Weisdorf, Saro H Armenian, Smita Bhatia","doi":"10.1093/jnci/djaf021","DOIUrl":null,"url":null,"abstract":"Background: Human papillomavirus (HPV) is associated with an increased risk for a variety of squamous cell carcinomas in the general population. The risk for subsequent squamous cell carcinomas in blood or marrow transplantation survivors that are potentially related to HPV (cervical, oropharyngeal, vulvar, vaginal, anal, and penile cancer; HPV-related squamous cell carcinomas) remains unknown.Methods: We determined the risk of HPV-related squamous cell carcinomas in 7936 2-year survivors of autologous or allogeneic blood or marrow transplantation performed between 1974 and 2014 and identified the role of demographic and clinical factors associated with HPV-related squamous cell carcinomas using proportional subdistribution hazards model for competing risks. Standardized incidence ratio was used to compare the risk of HPV-related squamous cell carcinoma with age-, sex-, and calendar-specific incidence in the general population.Results: The median age at transplantation was 46 years (range = 0-78 years); 58.5% (n = 4642) were male, and 72.2% (n = 5727) were non-Hispanic White. Half (50.3%, n = 3991) of the patients had received an allogeneic blood or marrow transplantation. The standardized incidence ratio for oropharyngeal squamous cell carcinomas (n = 53) was 1.8 (95% confidence interval [CI] = 1.3 to 2.3) and for cervical squamous cell carcinoma among female blood or marrow transplantation recipients (n = 26) was 9.4 (95% CI = 6.3 to 13.6) compared with the general US population. The hazard of an HPV-related squamous cell carcinoma was higher among allogeneic blood or marrow transplantation recipients with chronic graft vs host disease (any HPV-related squamous cell carcinoma: HR = 6.24, 95% CI = 3.11 to 12.50; oropharyngeal: HR = 4.85, 95% CI = 2.11 to 11.15; cervical: HR = 4.98, 95% CI = 1.65 to 15.00; reference: autologous blood or marrow transplantation). Pre-blood or marrow transplantation radiation increased the risk of oropharyngeal squamous cell carcinoma (HR = 2.98, 95% CI = 1.57 to 5.65).Conclusion: These findings underscore the importance of risk-based HPV vaccination and surveillance after blood or marrow transplantation.","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1166-1174"},"PeriodicalIF":9.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145910/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNCI Journal of the National Cancer Institute","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jnci/djaf021","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Human papillomavirus (HPV) is associated with an increased risk for a variety of squamous cell carcinomas in the general population. The risk for subsequent squamous cell carcinomas in blood or marrow transplantation survivors that are potentially related to HPV (cervical, oropharyngeal, vulvar, vaginal, anal, and penile cancer; HPV-related squamous cell carcinomas) remains unknown.

Methods: We determined the risk of HPV-related squamous cell carcinomas in 7936 2-year survivors of autologous or allogeneic blood or marrow transplantation performed between 1974 and 2014 and identified the role of demographic and clinical factors associated with HPV-related squamous cell carcinomas using proportional subdistribution hazards model for competing risks. Standardized incidence ratio was used to compare the risk of HPV-related squamous cell carcinoma with age-, sex-, and calendar-specific incidence in the general population.

Results: The median age at transplantation was 46 years (range = 0-78 years); 58.5% (n = 4642) were male, and 72.2% (n = 5727) were non-Hispanic White. Half (50.3%, n = 3991) of the patients had received an allogeneic blood or marrow transplantation. The standardized incidence ratio for oropharyngeal squamous cell carcinomas (n = 53) was 1.8 (95% confidence interval [CI] = 1.3 to 2.3) and for cervical squamous cell carcinoma among female blood or marrow transplantation recipients (n = 26) was 9.4 (95% CI = 6.3 to 13.6) compared with the general US population. The hazard of an HPV-related squamous cell carcinoma was higher among allogeneic blood or marrow transplantation recipients with chronic graft vs host disease (any HPV-related squamous cell carcinoma: HR = 6.24, 95% CI = 3.11 to 12.50; oropharyngeal: HR = 4.85, 95% CI = 2.11 to 11.15; cervical: HR = 4.98, 95% CI = 1.65 to 15.00; reference: autologous blood or marrow transplantation). Pre-blood or marrow transplantation radiation increased the risk of oropharyngeal squamous cell carcinoma (HR = 2.98, 95% CI = 1.57 to 5.65).

Conclusion: These findings underscore the importance of risk-based HPV vaccination and surveillance after blood or marrow transplantation.

查看原文本刊更多论文

血液或骨髓移植后人乳头瘤病毒相关的鳞状细胞癌——BMTSS报告

背景：在普通人群中，人乳头瘤病毒（HPV）与各种鳞状细胞癌（SCCs）的风险增加有关。可能与HPV（宫颈、口咽、外阴、阴道、肛门和阴茎癌）相关的BMT幸存者随后发生SCCs的风险；hpv相关SCCs)仍然未知。方法：我们确定了1974年至2014年间7936例自体或异体BMT的2岁幸存者发生hpv相关SCCs的风险，并使用比例亚分布风险模型确定了与hpv相关SCCs相关的人口统计学和临床因素的作用。标准化发病率（SIR）用于比较hpv相关SCC的风险与一般人群中年龄、性别和日历特定的发病率。结果：移植时中位年龄为46岁（范围0-78岁）；58.5% （n = 4642）为男性，72.2% （n = 5727）为非西班牙裔白人。一半的患者（50.3%,n = 3991）接受了同种异体BMT。与美国普通人群相比，口咽SCC （n = 53）的SIR为1.8 (95%CI = 1.3-2.3)，女性BMT受体宫颈SCC （n = 26）的SIR为9.4 （95%CI = 6.3-13.6）。患有慢性移植物抗宿主病（cGvHD）的同种异体BMT受体发生hpv相关SCC的风险更高(任何hpv相关SCC: HR = 6.24, 95%CI = 3.11-12.50；口咽部：HR = 4.85, 95%CI = 2.11-11.15；宫颈：HR = 4.98, 95%CI = 1.65-15.00；参考=自体BMT)。bmt前放疗增加口咽SCC的风险（HR = 2.98, 95%CI = 1.57-5.65）。结论：这些发现强调了基于风险的HPV疫苗接种和BMT后监测的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JNCI Journal of the National Cancer Institute 医学-肿瘤学

CiteScore

17.00

自引率

2.90%

发文量

203

审稿时长

4-8 weeks

期刊介绍： The Journal of the National Cancer Institute is a reputable publication that undergoes a peer-review process. It is available in both print (ISSN: 0027-8874) and online (ISSN: 1460-2105) formats, with 12 issues released annually. The journal's primary aim is to disseminate innovative and important discoveries in the field of cancer research, with specific emphasis on clinical, epidemiologic, behavioral, and health outcomes studies. Authors are encouraged to submit reviews, minireviews, and commentaries. The journal ensures that submitted manuscripts undergo a rigorous and expedited review to publish scientifically and medically significant findings in a timely manner.